Lexaptepid pegol: Phase IIa data

An open-label, European Phase IIa trial in 12 anemic patients with multiple myeloma (MM), low-grade lymphoma or chronic lymphocytic leukemia (CLL) showed that twice-weekly 1.2 mg/kg IV NOX-H94 for 4 weeks led to an anemia response, the primary endpoint defined as a >=1 g/dL increase in hemoglobin levels from baseline through 1 week post-treatment, in 42% of patients. For reference, Noxxon said published data in a similar population showed that erythropoietin (EPO) plus IV iron led to response in 65% of patients. ...